RxDoctor Payments Data

Tracy Cortezavad, APRN

Psychiatric/Mental Health · Medina, OHNPI 1558069690

Payments from drug & device makers

$3,766in general payments, 2019–2025

Across 41 payments — averaging $91.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$610
  • Axsome Therapeutics, Inc.$504
  • AbbVie$431
  • Otsuka America Pharmaceutical, Inc.$414
  • Johnson & Johnson$351
  • Sanofi-aventis U.S. LLC$322
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,65497%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,766 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$164,904
Medicare patients
439
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$106,284
AuvelityDextromethorphan Hbr/Bupropion36$21,763
RexultiBrexpiprazole15$10,932
Mirtazapine105$4,291
Divalproex Sodium93$3,886
Sertraline Hcl340$3,335
Buspirone Hcl104$2,724
BelsomraSuvorexant12$2,620
Aripiprazole58$2,219
Lurasidone Hcl13$2,181
Trazodone Hcl226$2,073
Memantine Hcl46$2,024
Quetiapine Fumarate60$1,501
Fluoxetine Hcl57$1,321
Divalproex Sodium ErDivalproex Sodium14$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$187$106,28418 claims
Axsome Therapeutics, Inc.Auvelity$504$21,76336 claims
Otsuka America Pharmaceutical, Inc.Rexulti$414$10,93215 claims
Lilly USA, LLCOlanzapine$69$26715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Medina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →